论文部分内容阅读
药对是中医临床遣药组方常用的配伍形式和复方来源之一,基于体内药动学研究是阐述药对配伍增效减毒机制的1个重要内容。该文全面总结整理丹参-红花(君臣配伍)和丹参-冰片(君使配伍)2类经典丹参药对的“标识成分”药动学研究报道,评价其阐释药对配伍的合理性和科学性,为今后药对配伍的药动学机制提出可行性建议。基于药对的药效组分“标识成分”的药动学比较研究,基本上考虑了中药的复杂体系存在背景、未脱离与其天然共存的化学体系,可以较好阐述药对配伍的君臣、君使增效机制,佐证了中药的“药辅共生”理论,这种药动学研究思路能较好地诠释药对配伍的增效机制。而基于单体化学成分、脱离中药复杂化学环境的“标识成分”药动学研究阐释药对配伍的增效机制尚存在一定空间,其科学性和合理性有待商榷。
Drug pair is one of the most commonly used forms of compatibility and compound source for the traditional Chinese medicine practitioners. Based on the pharmacokinetic study in vivo, it is an important part of explaining the mechanism of drug compatibility and increasing the attenuation. This article comprehensively summarizes and reports on the “identification components” pharmacokinetics of two types of classic Salvia miltiorrhiza Bunge., Which are composed of Salvia miltiorrhiza - safflower (Monarch concomitant) and Salvia miltiorrhiza - borneol (compatibility of Monarch), and evaluates the rationality of its explanation drug compatibility And scientific, for future drug compatibility pharmacokinetic mechanism put forward feasible suggestion. Based on the comparison of the pharmacokinetics of the pharmacodynamic component “identity component ”, basically considering the background of the complex system of traditional Chinese medicine and not detaching from the chemical system with its natural coexistence, , Jun make the synergistic mechanism, corroborated the traditional Chinese medicine “medicine auxiliary symbiotic ” theory, this pharmacokinetic research ideas can better explain the drug synergistic compatibility mechanism. However, based on monomer chemical composition, there is still some space for elucidating the synergistic mechanism of drug compatibility based on the “identity component” pharmacokinetic study that separates from the complex chemical environment of traditional Chinese medicine. Its scientificity and rationality need to be discussed.